AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01259830
Drug: Arcoxia®120 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
Trial: NCT01259830
Drug: P Tablet White Lichtenstein
RxNorm normalized name: phentermine Oral Tablet [Adipex-P]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
Trial: NCT04510168
Drug: [F-18]MK-6240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET imaging to measure tau; target imaging dose of 4 to 5 mCi
Trial: NCT02101476
Drug: Xartemis
RxNorm normalized name: Xartemis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg/650mg
Trial: NCT02361736
Drug: Lactate Ringers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
Trial: NCT02474654
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15mcg
Trial: NCT02474654
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 ml
Trial: NCT02474654
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30ml
Trial: NCT02474654
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml
Trial: NCT02474654
Drug: Ropivicaine
RxNorm normalized name: Ropivicaine-Sufentanil Citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml
Trial: NCT02474654
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mcg
Trial: NCT02474654
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg
Trial: NCT02474654
Drug: Ropivicaine with Epinephrine
RxNorm normalized name: Sensorcaine with Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% 1:400,000 30ml
Trial: NCT01910831
Drug: DerMend Moisturizing Bruise Formula
RxNorm normalized name: DerMend Moisturizing Bruise Formula Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.
Trial: NCT01910831
Drug: Non-active placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active placebo control
Trial: NCT01274962
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Oxaliplatin\* 85 mg/m2 IV in 500 mL of D5W over 120 minutes~* Folinic Acid (Leucovorin)\* 400 mg/m2 IV in 250 ml D5W over 120 minutes~* 5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid~* 5-Fluorouracil\*\* 2400 mg/m2 IV over 46 h in D5W to a total volume of 92 mL by continuous infusion at 2 mL/hour.~* Repeat every 14 days for 6 cycles in the arm A and to be completed with 6 cycles after surgery and 12 cycles in arm B.~If necessary the schedule may be modified +/- 3 days.
Trial: NCT01186562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04107727
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction: oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days.
Trial: NCT01007019
Drug: YH4808 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 30mg (single dose)
Trial: NCT01007019
Drug: YH4808 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 50mg (single dose)
Trial: NCT01007019
Drug: YH4808 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 100mg (single dose)
Trial: NCT01007019
Drug: YH4808 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 200mg (single dose)
Trial: NCT01007019
Drug: YH4808
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 400mg (single dose)
Trial: NCT01007019
Drug: YH4808 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 600mg
Trial: NCT01007019
Drug: YH4808 800mg (single dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 800mg (single dose)
Trial: NCT01007019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 volunteers will be administered matched placebo.
Trial: NCT01160640
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg PO bid x 14 days
Trial: NCT01160640
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral capsule PO bid x 14 days
Trial: NCT00959621
Drug: Klexane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3
Trial: NCT00002592
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00536198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
Trial: NCT02922582
Drug: DepoTXA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00133679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suspension (equal volume to experimental drug) x 45 days
Trial: NCT00200655
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00200655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04315272
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
Trial: NCT04315272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02376257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug
Trial: NCT00374166
Drug: SSR149415
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration (capsules of 50 and 100 mg)
Trial: NCT00374166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration (capsules)
Trial: NCT02643082
Drug: GFF MDI (PT003) 14.4/9.6μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium and Formoterol Fumarate
Trial: NCT02643082
Drug: Placebo MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator: Placebo MDI which contains no active ingredients
Trial: NCT01120691
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
Trial: NCT01120691
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
Trial: NCT01435928
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo once daily in the evening with a meal or 30 minutes after eating
Trial: NCT04429139
Drug: photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDT with Visudyne® was performed under general anesthesia according to the standard TAP study with some modifications: Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion followed by followed by application of diode laser (Opal Photoactivator; Coherent Medical Group, Santa Clara, USA) (689 nm, 50 J/cm2, 600 mW/cm2) for 200 seconds to generate 120 J/cm2.
Trial: NCT01588548
Drug: AZD1208
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose
Trial: NCT03735225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Dasiglucagon injection
Trial: NCT00368355
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: day-7 and day-6~45 mg/kg
Trial: NCT03305822
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00804999
Drug: Clear Care
RxNorm normalized name: Clear care plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neutralized Clear Care
Trial: NCT01252108
Drug: SQ109
RxNorm normalized name: SQ109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg SQ109 daily for 14 days
Trial: NCT01991028
Drug: Radiolabelled OligoG CF-5/20 DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation with dry powder by Mia Monodose Inhaler
Trial: NCT01991028
Drug: Radiolabelled OligoG CF-5/20 6% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation with aerosolised solution by nebuliser
Trial: NCT02177045
Drug: Sonovue, Bracco
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT03600974
Drug: Probiotic Agent
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Agent for I(+)G/W；Live Bacillus Licheniformis Cranules 0.5g bid； Bifidbacterium 0.63g bid
Trial: NCT03600974
Drug: PPI
RxNorm normalized name: PPIase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid
Trial: NCT03600974
Drug: Prokinetic Motility Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid
Trial: NCT03600974
Drug: Neuromodulators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;
Trial: NCT01700192
Drug: Rescue Medication: Self-Injectable Epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.
Trial: NCT02738515
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After Scaling and Root Planing placement of Placebo gel in Mandibular degree 2 Furcation defect.
Trial: NCT00848081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: By mouth once daily for 12 weeks
Trial: NCT00361153
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03415191
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A bolus dose of normal saline 1 mg/kg intravenously five minutes before surgical incision
Trial: NCT00660998
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02635945
Drug: PBF-680
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02635945
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00573469
Drug: D9421-C, 9mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D9421-C 9 mg was given once daily for 8 weeks.
Trial: NCT00573469
Drug: D9421-C, 15mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D9421-C 15 mg was given once daily for 8 weeks.
Trial: NCT00573469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D9421-C matching placebo was given once daily for 8 weeks.
Trial: NCT02064868
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
Trial: NCT02442362
Drug: paclitaxel+oxaliplatin+fluorouracil
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients treated with paclitaxel+oxaliplatin+fluorouracil: paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14.
Trial: NCT00188149
Drug: Combined chemotherapy (ABVD, BACOPP-D)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00754624
Drug: Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation starting at 15, 30, or 60U doses and can be titrated up or down by 15U to a minimum of 15U or a maximum of 90U
Trial: NCT01541124
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/pill, po, each 6h, during 6m
Trial: NCT01320085
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04056689
Drug: DNL151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT04056689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT02329561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single placebo tablet identical in appearance to a 200mg tramadol extended-release tablet
Trial: NCT04566211
Drug: (panto+amox+clar+metr)+(panto+amox)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
Trial: NCT01016054
Drug: Pegylated liposomal doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT00268515
Drug: azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02528409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04333134
Drug: SHR3162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzoparib, also known as SHR3162, is an inhibitor of human PARP
Trial: NCT00005892
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01635101
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Acetaminophen given every 6 hours (q6h); 4 doses, in 24 hours
Trial: NCT00434590
Drug: Enteric coated mycophenolate sodium (Myfortic®)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04163588
Drug: Loop Diuretics
RxNorm normalized name: LOOP DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants receive a standard diuretic strategy (intravenous loop diuretics as recommended by current guidelines plus placebo)
Trial: NCT04791007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal or rectal administration
Trial: NCT01234324
Drug: Epirubicin, Cisplatin, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
Trial: NCT00851006
Drug: Creatine Monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creapure brand of creatine monohydrate
Trial: NCT00003700
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg/sq m IV infusion over 15-30 min Day 1 Courses I \& IV (pts \< 60y/o) 1000 mg/sq m IV infusion over 15-30 min Day 1 Courses II \& V
Trial: NCT00003700
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Courses III \& VI:~25mg/sq m IV infusion Days 2, 9, and 16 5mg/sq m PO q 6 hr for 8 doses or until serum MTX \<0.05 uM after ea IV dose
Trial: NCT00003700
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60mg/sq m/d PO every day Course VII
Trial: NCT00003700
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15mg intrathecal Day 1 Courses II \& V 1000mg/sq m IV infusion over 3 hrs Days 1, 8, \& 15 and 25mg/sq m PO q 6hr x 4 doses after ea IV dose: Courses III \& VI.
Trial: NCT03495206
Drug: Y-2(Edaravone And Borneol) Sublingual Tablet
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Y-2 sublingual tablet at single ascending doses of one tablet , two tablets, three tablets, four tablets
Trial: NCT00754052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will start with a dose of 2.5 mg/day (2.5 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) placebo. All doses will be administered orally.
Trial: NCT02998606
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 25 mg, daily
Trial: NCT00063609
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00359671
Drug: MK6592
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.
Trial: NCT02653391
Drug: Part A Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A Each subject will receive one drop of vehicle ophthalmic solution BID in the paired eye of the randomly selected study eye.
Trial: NCT02653391
Drug: Part B Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: Each subject will receive one drop of vehicle ophthalmic solution BID in both eyes.
Trial: NCT01938599
Drug: AM001 Cream, 7.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream, 2x daily for 12 weeks
Trial: NCT01938599
Drug: Placebo of AM001 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream, 2x daily for 12 weeks
Trial: NCT00557245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo TDF \& Placebo FTC/TDF, 1 tablet each daily.
Trial: NCT03523650
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Placebo Oral Tablet, tid, for 36 months.
Trial: NCT01802216
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic microspheres
Trial: NCT03971734
Drug: Regadensoson 0.1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regadensoson 0.1mg administered prior to MRI
Trial: NCT03971734
Drug: Regadensoson 0.2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regadensoson 0.2mg administered prior to MRI
Trial: NCT03971734
Drug: Regadensoson 0.4mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regadensoson 0.4mg administered prior to MRI
Trial: NCT03971734
Drug: Regadensoson 0.7mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regadensoson 0.7mg administered prior to MRI
Trial: NCT03971734
Drug: Regadensoson 1.0mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regadensoson 1.0mg administered prior to MRI
Trial: NCT03971734
Drug: Regadensoson 1.4mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regadensoson 1.4mg administered prior to MRI
Trial: NCT01713166
Drug: plasmalyte solution
RxNorm normalized name: Plasmalyte A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: plasmalyte solution
Trial: NCT00440622
Drug: Capecitabine (Xeloda)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles
Trial: NCT00683592
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00498316
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg by vein on Day -6 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.